AQST Q4 2020 Earnings — Aquestive Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

AQSTAquestive Therapeutics, Inc.

$431M

Q4 2020 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$7M-56.5% YoY

Gross Profit

$4M61.0% margin

Operating Income

-$16M-218.9% margin

Net Income

-$20M-284.9% margin

EPS (Diluted)

$-0.60

QoQ Revenue Growth

-13.5%

Cash Flow

Operating Cash Flow

-$14M

Free Cash Flow

-$14M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$63M

Total Liabilities

$111M

Stockholders' Equity

-$48M

Cash & Equivalents

$32M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$7M	$16M	-56.5%
Gross Profit	$4M	$10M	-54.7%
Operating Income	-$16M	-$10M	-58.0%
Net Income	-$20M	-$13M	-61.2%

Revenue Segments

Manufacture and Supply Revenue

$5M67%

Proprietary Product Sales

$2M22%

Co-Development and Research Fees

$394,0006%

License and Royalty Revenue

$373,0005%

Geographic Segments

United States

$5M76%

Non-US

$2M24%